<DOC>
	<DOCNO>NCT01183650</DOCNO>
	<brief_summary>The purpose study investigate pharmacokinetics tadalafil Japanese non-Japanese men Benign Prostatic Hyperplasia ( BPH ) . The safety tadalafil also study .</brief_summary>
	<brief_title>A Study Tadalafil Benign Prostatic Hyperplasia</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>Have low urinary tract symptom secondary benign prostatic hyperplasia ( BPHLUTS ) ( diagnose qualified physician ) &gt; 6 month screen visit . Lower urinary tract symptom ( LUTS ) include associate voiding ( obstructive symptom , incomplete emptying , intermittency , weak stream , strain ) and/or storage ( irritative symptom , frequency , urgency , nocturia ) . Have BPHLUTS moderatetosevere symptoms confirmed International Prostate Symptom Score ( IPSS ) &gt; 12 . ( The IPSS total score define sum Questions 1 7 include IPSS Quality Life . ) Taking account age disease status , subject determine good health accord medical history , physical examination , electrocardiogram ( ECG ) , laboratory safety assessment . Body mass index 18 30 kg/m^2 inclusive . Agree use approve experimental pharmacologic BPH , erectile dysfunction ( ED ) , and/or overactive bladder ( OAB ) treatment , include alpha blocker , phosphodiesterase type 5 ( PDE5 ) inhibitor , herbal preparation least 1 week prior dose followup . Subjects serum prostatespecific antigen ( PSA ) &lt; 10.0 ng/mL . Subjects serum PSA great equal 4.0 &lt; 10.0 ng/mL must documentation negative histologic biopsy carcinoma prostate within 12 month prior screen . History radical prostatectomy , pelvic surgery procedure , include pelvic surgical procedure urinary tract apart transurethral resection , pelvic surgery malignancy bowel resection , history lower urinary tract malignancy trauma . History urinary retention lower urinary tract ( bladder ) stone within 6 month screen . Current previous history malignant disease prostate . Concomitant treatment ingestion cytochrome P 450 3A4 ( CYP3A4 ) induce inhibit agent 2 week prior dose end study . Including herbal/food supplement , fruit , fruit juice contain grapefruit pomegranate component . History loss vision one eye nonarteritic anterior ischemic optic neuropathy ( NAION ) , regardless whether episode connection previous PDE5 inhibitor exposure . Subjects chronic stable angina treat longacting nitrate , subject chronic stable angina require shortacting nitrate 90 day prior screen visit , subject angina occur sexual intercourse 6 month prior screen . Subjects meet criterion unstable angina within 6 month prior screen , history myocardial infarction coronary artery bypass graft surgery within 90 day prior screen , percutaneous coronary intervention ( example , angioplasty stent placement ) within 90 day prior screen . Any evidence heart disease ( New York Heart Association [ NYHA ] great equal Class III ) within 6 month screen . A history cardiac arrest .</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>